Novoxel

Novoxel is a medical technology company specializing in fractional skin rejuvenation and ophthalmology using proprietary Thermo-Mechanical Action (TMA) technology.

Health Tech & Life Sciences
Active
Mature Netanya, Israel Founded 2011
Last updated 2026-07-20
Total raised
Stage
Mature
Founded
2011
Headcount
27
HQ
Netanya, Israel
Sector
Health Tech & Life Sciences

About

Novoxel is an Israeli medical technology company established in 2011, with its headquarters in Netanya, Israel. The company specializes in innovative treatments for fractional skin rejuvenation and ophthalmology, utilizing its proprietary Thermo-Mechanical Action (TMA) technology. Novoxel aims to enhance aesthetic and medical treatments by combining heat and motion in a non-laser, patient-friendly approach that is safe and effective. The company develops and markets patented medical devices in over 50 countries. Its flagship product, the Tixel® Platform, offers fractional skin resurfacing for various body areas, and the Tixel i® Device, recently FDA-cleared, treats evaporative dry eye by applying localized heat and pressure to the eyelids. Novoxel targets medical professionals, including dermatologists and ophthalmologists, and collaborates with the medical community to ensure clinical excellence and innovation. The company also has a US facility in Knoxville, Tennessee, established in 2024.

Headcount over time

From 11 (2018-09) to 27 (2026-07) · +16 (+145%) · 33 points · source: Finder history + radar grounding
300 2018-09 2026-07

Q&A

What is Novoxel's primary focus?
Novoxel specializes in Skin Rejuvenation Technology, developing fractional, microtip aesthetic technology for thermomechanical ablation (TMA).
When was Novoxel founded?
Novoxel was founded in August 2011.
Where is Novoxel headquartered?
Novoxel is headquartered in Netanya, Center District, Israel.
What is Novoxel's Tixel technology?
Novoxel's Tixel technology is a non-laser fractional treatment that transfers thermal energy to the skin for precise, accurate, and painless tissue evaporation without undesired thermal damage.
What is Novoxel's Mezotix technology?
Novoxel's Mezotix technology transfers pure heat to the skin through brief contact, inducing renewal of epidermal cells and regeneration of collagen in the dermis.
Who are the co-founders of Novoxel?
The co-founders of Novoxel are Michael Slatkine and Jacob Zlochover.
In which sector does Novoxel primarily operate?
Novoxel's primary sector is Health Tech & Life Sciences, specifically within Medical Devices and Medical Treatment & Therapeutics.

Team · 2

Zlochover Jacob
Founder · Co-Founder
Michael Slatkine
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

Verified

Tags

patent-pendingskin-caredermatologyclinicsmedical-devicespain-freetissue-regenerationhealthcare-providersmobile-applications
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitetixelmed.com/gl
LinkedInlinkedin.com/company/3497374
Facebookfacebook.com/novoxel
YouTubeyoutube.com/channel/UCOOWnHkryneOISQjifYNS5A
Instagraminstagram.com/novoxel

Identifiers & details

Legal nameNovoxel Ltd.
Founded2011
Employees (exact)27
OfficesGermany; Berlin

Radar intelligence

Patents

EPO9

Publications (Crossref)

Works5

Web history (Wayback)

Domaintixelmed.com

Certificate / subdomain footprint

Subdomains17

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514653815
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2011-08-08
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events4 — people (1), shares_capital (2), other (1)
Registered addressהמלאכה 43 נתניה

Recent registry events

DateEvent
2026-02-23עדכון דירקטורים-הוספת דירקטור
2026-07-16הקצאת מניות
2026-07-13העברת מניות
2025-09-08שינוי בתקנון